<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>44</viewCount><searchCount>0</searchCount></scores><additional><omics_type>Unknown</omics_type><volume>7(30)</volume><submitter>Sablin MP</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>We aimed at identifying druggable molecular alterations at the RNA level from untreated HNSCC patients, and assessing their prognostic significance.&lt;h4>Methods&lt;/h4>We retrieved 96 HNSCC patients who underwent primary surgery. Real-time quantitative RT-PCR was used to analyze a panel of 42 genes coding for major druggable proteins. Univariate and multivariate analyses were performed to assess the prognostic significance of overexpressed genes.&lt;h4>Results&lt;/h4>Median age was 56 years [35-78]. Most of patients were men (80%) with a history of alcohol (70.4%) and/or tobacco consumption (72.5%). Twelve patients (12%) were HPV-positive. Most significantly overexpressed genes involved cell cycle regulation (CCND1 [27%], CDK6 [21%]), tyrosine kinase receptors (MET [18%], EGFR [14%]), angiogenesis (PGF [301%], VEGFA [14%]), and immune system (PDL1/CD274 [28%]). PIK3CA expression was an independent prognostic marker, associated with shorter disease-free survival.&lt;h4>Conclusions&lt;/h4>We identified druggable overexpressed genes associated with a poor outcome that might be of interest for personalizing treatment of HNSCC patients.</pubmed_abstract><journal>Oncotarget</journal><pagination>47418-47430</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5216951</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.</pubmed_title><pmcid>PMC5216951</pmcid><pubmed_authors>Sastre-Garau X</pubmed_authors><pubmed_authors>Mariani O</pubmed_authors><pubmed_authors>Caly M</pubmed_authors><pubmed_authors>Rodriguez J</pubmed_authors><pubmed_authors>Girod A</pubmed_authors><pubmed_authors>Kamal M</pubmed_authors><pubmed_authors>Lappartient E</pubmed_authors><pubmed_authors>Vacher S</pubmed_authors><pubmed_authors>Sablin MP</pubmed_authors><pubmed_authors>Hoffmann C</pubmed_authors><pubmed_authors>Berger F</pubmed_authors><pubmed_authors>Chemlali W</pubmed_authors><pubmed_authors>Ouafi L</pubmed_authors><pubmed_authors>Bieche I</pubmed_authors><pubmed_authors>Klijanienko J</pubmed_authors><pubmed_authors>Jouffroy T</pubmed_authors><pubmed_authors>Calugaru V</pubmed_authors><pubmed_authors>Le Tourneau C</pubmed_authors><pubmed_authors>Lidereau R</pubmed_authors><pubmed_authors>Dubot C</pubmed_authors><view_count>44</view_count></additional><is_claimable>false</is_claimable><name>Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.</name><description>&lt;h4>Background&lt;/h4>We aimed at identifying druggable molecular alterations at the RNA level from untreated HNSCC patients, and assessing their prognostic significance.&lt;h4>Methods&lt;/h4>We retrieved 96 HNSCC patients who underwent primary surgery. Real-time quantitative RT-PCR was used to analyze a panel of 42 genes coding for major druggable proteins. Univariate and multivariate analyses were performed to assess the prognostic significance of overexpressed genes.&lt;h4>Results&lt;/h4>Median age was 56 years [35-78]. Most of patients were men (80%) with a history of alcohol (70.4%) and/or tobacco consumption (72.5%). Twelve patients (12%) were HPV-positive. Most significantly overexpressed genes involved cell cycle regulation (CCND1 [27%], CDK6 [21%]), tyrosine kinase receptors (MET [18%], EGFR [14%]), angiogenesis (PGF [301%], VEGFA [14%]), and immune system (PDL1/CD274 [28%]). PIK3CA expression was an independent prognostic marker, associated with shorter disease-free survival.&lt;h4>Conclusions&lt;/h4>We identified druggable overexpressed genes associated with a poor outcome that might be of interest for personalizing treatment of HNSCC patients.</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jul</publication><modification>2024-11-20T10:06:50.129Z</modification><creation>2019-03-27T02:33:24Z</creation></dates><accession>S-EPMC5216951</accession><cross_references><pubmed>27329726</pubmed><doi>10.18632/oncotarget.10163</doi></cross_references></HashMap>